, 8:339 | Cite as

Cyclooxygenase inhibition in early onset of tumor growth and related angiogenesis evaluated in EP1 and EP3 knockout tumor-bearing mice

  • Hans Axelsson
  • Christina Lönnroth
  • Wenhua Wang
  • Elisabeth Svanberg
  • Kent LundholmEmail author


It is well established that prostanoids are essential for local inflammation including cell proliferation and apoptosis. Accordingly, prostaglandin E2 (PGE2) is a critical factor in wound healing, tumor invasiveness and progression. Therefore, the aim of the present work was to evaluate effects by PGE2 on tumor vascular density at early onset of tumor growth where hypoxia is limited. Wild-type mice (C57Bl, C3H/HeN) bearing either MCG-101 tumors or a malignant melanoma (K1735-M2) with either high or insignificant PGE2 production and subsequently different in sensitivity to cyclooxygenase (COX) inhibition were used. Tumor angiogenesis was estimated by intravital microscopy and immune histochemical analysis in wild type and EP1 or EP3 subtype receptor knockout mice (C57Bl). Both MCG-101 and K1735-M2 tumor cells stimulated early outgrowth of tumor vessels in proportion to intrinsic growth rate of tumor cells. Indomethacin had no effects on tumor growth or tumor related vascular area in K1735-M2 bearing mice. By contrast, indomethacin decreased tumor cell proliferation and increased apoptosis in MCG-101 tumors with subsequent adaptation in tumor vascular density. Effects of indomethacin on early growth of MCG-101 tumors were not related to tumor content of bFGF protein, while our earlier studies on long-term tumor growth have shown decreased mRNA levels of bFGF during indomethacin treatment. Early onset of tumor growth was significantly promoted in EP3- but not in EP1-knockouts, although long-term tumor growth is attenuated in EP1-knockouts as reported elsewhere. Our results demonstrate that tumor production of PGE2 promotes primarily net growth of tumor cells with subsequent adaptations in development of the tumor vasculature. Therefore, it is likely that angiogenesis is not a limiting step at the early onset of tumor growth.


angiogenesis COX EP-subtype receptor gene knockout 



This article was supported in parts by grants from the Swedish Cancer Society (2014, 4261), the Swedish Research Council (08712, 13268), Assar Gabrielsson Foundation (AB Volvo), Jubileumskliniken Foundation, IngaBritt & Arne Lundberg Research Foundation, Swedish and Göteborg Medical Societies and the Medical Faculty, Göteborg University.


  1. 1.
    Folkman J. (1971) Tumor angiogenesis: Therapeutic implications. N Engl J Med 285:1182–6PubMedGoogle Scholar
  2. 2.
    Gasparini G, Longo R, Fanelli M, Teicher BA (2005). Combination of antiangiogenic therapy with other anticancer therapies: Results, challenges, and open questions. J Clin Oncol 23: 1295–311PubMedCrossRefGoogle Scholar
  3. 3.
    Peterson HI (1986). Tumor angiogenesis inhibition by prostaglandin synthetase inhibitors. Anticancer Res 6:251–3PubMedGoogle Scholar
  4. 4.
    Wang HM, Zhang GY (2005). Indomethacin suppresses growth of colon cancer via inhibition of angiogenesis in vivo. World J Gastroenterol 11: 340–3PubMedGoogle Scholar
  5. 5.
    Cahlin C, Korner A, Axelsson H et al. (2000). Experimental cancer cachexia: The role of host-derived cytokines interleukin (IL)-6, IL-12, interferon-gamma, and tumor necrosis factor alpha evaluated in gene knockout, tumor-bearing mice on C57 Bl background and eicosanoid-dependent cachexia. Cancer Res 60: 5488–93PubMedGoogle Scholar
  6. 6.
    Peluffo GD, Stillitani I, Rodriguez VA et al. (2004). Reduction of tumor progression and paraneoplastic syndrome development in murine lung adenocarcinoma by nonsteroidal antiinflammatory drugs. Int J Cancer 110: 825–30PubMedCrossRefGoogle Scholar
  7. 7.
    McMillan DC, Leen E, Smith J, et al. (1995). Effect of extended ibuprofen administration on the acute phase protein response in colorectal cancer patients. Eur J Surg Oncol 21: 531–4PubMedCrossRefGoogle Scholar
  8. 8.
    Gelin J, Andersson C, Lundholm K (1991). Effects of indomethacin, cytokines, and cyclosporin A on tumor growth and the subsequent development of cancer cachexia. Cancer Res 51: 880–5PubMedGoogle Scholar
  9. 9.
    Cahlin C, Gelin J, Delbro D et al. (2000). Effect of cyclooxygenase and nitric oxide synthase inhibitors on tumor growth in mouse tumor models with and without cancer cachexia related to prostanoids. Cancer Res 60: 1742–9PubMedGoogle Scholar
  10. 10.
    Lönnroth C, Svaninger G, Gelin J, et al. (1995). Effects related to indomethacin prolonged survival and decreased tumor growth in a mouse tumor model with cytokine dependent cancer cachexia. Int J Oncol 7: 1405–13Google Scholar
  11. 11.
    Lundholm K, Gelin J, Hyltander A, et al. (1994). Anti-inflammatory treatment may prolong survival in undernourished patients with metastatic solid tumors. Cancer Res 54: 5602–6PubMedGoogle Scholar
  12. 12.
    Lundholm K, Daneryd P, Korner U et al. (2004). Evidence that long-term COX-treatment improves energy homeostasis and body composition in cancer patients with progressive cachexia. Int J Oncol 24: 505–12PubMedGoogle Scholar
  13. 13.
    Rajendran JG, Krohn KA (2005). Imaging hypoxia and angiogenesis in tumors. Radiol Clin North Am 43: 169–87PubMedCrossRefGoogle Scholar
  14. 14.
    Cahlin C, Gelin J, Andersson M et al. The effects of non-selective, preferential-selective and selective COX-inhibitors on the growth of experimental and human tumors in mice related to prostanoid receptors. Int J Oncol 2005; 27: 913–23Google Scholar
  15. 15.
    Lönnroth C, Andersson M, Lundholm K (2001). Indomethacin and telomerase activity in tumor growth retardation. Int J Oncol 18: 929–937PubMedGoogle Scholar
  16. 16.
    Ushikubi F, Segi E, Sugimoto Y, et al. (1998). Impaired febrile response in mice lacking the prostaglandin E receptor subtype EP3. Nature 395: 281–4PubMedCrossRefGoogle Scholar
  17. 17.
    Batshake B, Sundelin J (1996). The mouse genes for the EP1 prostanoid receptor and the PKN protein kinase overlap. Biochem Biophys Res Commun 227: 70–6PubMedCrossRefGoogle Scholar
  18. 18.
    Wang W, Andersson M, Lönnroth C et al. (2005). Anorexia and cachexia in prostaglandin EP1 and EP3 subtype receptor knockout mice bearing a tumor with high intrinsic PGE2 production and prostaglandin related cachexia. J Exp Clin Cancer Res 24: 99–107PubMedGoogle Scholar
  19. 19.
    Axelsson H, Bagge U, Lundholm K, Svanberg E (1997). A one-piece plexiglass access chamber for subcutaneous implantation in the dorsal skin fold of the mouse. Int J Microcirc Clin Exp 17: 328–9PubMedCrossRefGoogle Scholar
  20. 20.
    Sales KJ, Katz AA, Howard B et al. (2002). Cyclooxygenase-1 is up-regulated in cervical carcinomas: Autocrine/paracrine regulation of cyclooxygenase-2, prostaglandin e receptors, and angiogenic factors by cyclooxygenase-1. Cancer Res 62: 424–32PubMedGoogle Scholar
  21. 21.
    Needleman P, Turk J, Jakschik BA et al. (1986). Arachidonic acid metabolism. Annu Rev Biochem 55: 69–102PubMedCrossRefGoogle Scholar
  22. 22.
    Halushka PV, Mais DE, Mayeux PR, Morinelli TA (1989). Thromboxane, prostaglandin and leukotriene receptors. Annu Rev Pharm Tox 10: 213–39CrossRefGoogle Scholar
  23. 23.
    Narumiya S, FitzGerald GA (2001). Genetic and pharmacological analysis of prostanoid receptor function. J Clin Invest 108: 25–30PubMedGoogle Scholar
  24. 24.
    Taketo MM (1998). Cyclooxygenase-2 inhibitors in tumorigenesis (part I). J Natl Cancer Inst 90: 1529–36PubMedCrossRefGoogle Scholar
  25. 25.
    Watson AJ (1998). Chemopreventive effects of NSAIDs against colorectal cancer: Regulation of apoptosis and mitosis by COX-1 and COX-2. Histol Histopathol 13: 591–7PubMedGoogle Scholar
  26. 26.
    Palayoor ST, Tofilon PJ, Coleman CN (2003). Ibuprofen-mediated reduction of hypoxia-inducible factors HIF-1α and HIF-2α in prostate cancer cells. Clin Cancer Res 9: 3150–7PubMedGoogle Scholar
  27. 27.
    Kragh M, Hjarnaa PJ, Bramm E et al. (2003). In vivo chamber angiogenesis assay: An optimized Matrigel plug assay for fast assessment of anti-angiogenic activity. Int J Oncol 22:305–11PubMedGoogle Scholar
  28. 28.
    Raut CP, Nawrocki S, Lashinger LM et al. Celecoxib inhibits angiogenesis by inducing endothelial cell apoptosis in human pancreatic tumor xenografts. Cancer Biol Ther 2004; 3Google Scholar
  29. 29.
    Jones MK, Wang H, Peskar BM, et al (1999). Inhibition of angiogenesis by nonsteroidal anti-inflammatory drugs: Insight into mechanisms and implications for cancer growth and ulcer healing. Nat Med 5:1418–23PubMedCrossRefGoogle Scholar
  30. 30.
    Castro MR, Lutz D, Edelman JL (2004). Effect of COX inhibitors on VEGF-induced retinal vascular leakage and experimental corneal and choroidal neovascularization. Exp Eye Res 79:275–85PubMedCrossRefGoogle Scholar
  31. 31.
    Pearce HR, Kalia N, Bardhan KD, Brown NJ (2003). Effects of aspirin and indomethacin on endothelial cell proliferation in vitro. J Gastroenterol Hepatol 18:1180–7PubMedCrossRefGoogle Scholar
  32. 32.
    Szabo IL, Pai R, Soreghan B, et al. (2001). NSAIDs inhibit the activation of egr-1 gene in microvascular endothelial cells. A key to inhibition of angiogenesis? J Physiol Paris 95: 379–83PubMedCrossRefGoogle Scholar
  33. 33.
    Davel LE, Rimmaudo L, Espanol A, et al. (2004). Different mechanisms lead to the angiogenic process induced by three adenocarcinoma cell lines. Angiogenesis 7: 45–51PubMedCrossRefGoogle Scholar
  34. 34.
    Chen JJ, Yao PL, Yuan A, et al. (2003). Up-regulation of tumor interleukin-8 expression by infiltrating macrophages: Its correlation with tumor angiogenesis and patient survival in non-small cell lung cancer. Clin Cancer Res 9: 729–37PubMedGoogle Scholar
  35. 35.
    Golab J, Kozar K, Kaminski R, et al. (2000). Interleukin 12 and indomethacin exert a synergistic, angiogenesis-dependent antitumor activity in mice. Life Sci 66: 1223–30PubMedCrossRefGoogle Scholar
  36. 36.
    Lala PK, Al-Mutter N, Orucevic A (1997). Effects of chronic indomethacin therapy on the development and progression of spontaneous mammary tumors in C3H/HEJ mice. Int J Cancer 73: 371–80PubMedCrossRefGoogle Scholar
  37. 37.
    Spisni E, Manica F, Tomasi V (1992). Involvement of prostanoids in the regulation of angiogenesis by polypeptide growth factors. Prostaglandins Leukot Essent Fatty Acids 47: 111–5PubMedCrossRefGoogle Scholar
  38. 38.
    Chang SH, Liu CH, Conway R, et al. (2004). Role of prostaglandin E2-dependent angiogenic switch in cyclooxygenase 2-induced breast cancer progression. Proc Natl Acad Sci USA 101: 591–6PubMedCrossRefGoogle Scholar
  39. 39.
    Gallo O, Franchi A, Magnelli L, et al. (2001). Cyclooxygenase-2 pathway correlates with VEGF expression in head and neck cancer. Implications for tumor angiogenesis and metastasis. Neoplasia 3: 53–61PubMedCrossRefGoogle Scholar
  40. 40.
    Pai R, Szabo IL, Kawanaka H et al. (2000). Indomethacin inhibits endothelial cell proliferation by suppressing cell cycle proteins and PRB phosphorylation: A key to its antiangiogenic action? Mol Cell Biol Res Commun 4: 111–6PubMedCrossRefGoogle Scholar
  41. 41.
    Li G, Yang T, Yan J (2002). Cyclooxygenase-2 increased the angiogenic and metastatic potential of tumor cells. Biochem Biophys Res Commun 299: 886–90PubMedCrossRefGoogle Scholar
  42. 42.
    Sawaoka H, Tsuji S, Tsujii M, et al. (1999). Cyclooxygenase inhibitors suppress angiogenesis and reduce tumor growth in vivo. Lab Invest 79: 1469–77PubMedGoogle Scholar
  43. 43.
    Fosslien E (2000). Biochemistry of cyclooxygenase (COX)-2 inhibitors and molecular pathology of COX-2 in neoplasia. Crit Rev Clin Lab Sci 37: 431–502PubMedCrossRefGoogle Scholar
  44. 44.
    Watanabe K, Kawamori T, Nakatsugi S, et al. (1999). Role of the prostaglandin E receptor subtype EP1 in colon carcinogenesis. Cancer Res 59: 5093–6PubMedGoogle Scholar
  45. 45.
    Franzese O, Comandini A, Cannavo E, et al. (1998). Effect of prostaglandin A1 on proliferation and telomerase activity of human melanoma cells in vitro. Melanoma Res 8: 323–8PubMedCrossRefGoogle Scholar
  46. 46.
    Ogino M, Hisatomi H, Murata M, Hanazono M (1999). Indomethacin suppresses the growth of colon 26, Meth-A and FM3A tumors in mice by reducing the prostaglandin E2 content and telomerase activity in tumor tissues. Jpn J Cancer Res 90: 758–64PubMedGoogle Scholar
  47. 47.
    You BJ, Huang IJ, Liu WH et al. (1999). Decrease in nucleophosmin/B23 mRNA and telomerase activity during indomethacin-induced apoptosis of gastric KATO-III cancer cells. Naunyn Schmiedebergs Arch Pharmacol 360: 683–90PubMedCrossRefGoogle Scholar
  48. 48.
    Amano H, Hayashi I, Endo H, et al. (2003). Host prostaglandin E(2)-EP3 signaling regulates tumor-associated angiogenesis and tumor growth. J Exp Med 197: 221–32PubMedCrossRefGoogle Scholar
  49. 49.
    Takafuji V, Cosme R, Lublin D et al. (2000). Prostanoid receptors in intestinal epithelium: Selective expression, function, and change with inflammation. Prostaglandins Leukot Essent Fatty Acids 63: 223–35PubMedCrossRefGoogle Scholar
  50. 50.
    Dirkx AE, Oude Egbrink MG, Kuijpers MJ, et al. (2003). Tumor angiogenesis modulates leukocyte-vessel wall interactions in vivo by reducing endothelial adhesion molecule expression. Cancer Res 63: 2322–9PubMedGoogle Scholar
  51. 51.
    Fukumura D, Salehi HA, Witwer B et al. (1995). Tumor necrosis factor alpha-induced leukocyte adhesion in normal and tumor vessels: Effect of tumor type, transplantation site, and host strain. Cancer Res 55: 4824–9PubMedGoogle Scholar

Copyright information

© Springer Science+Business Media, Inc. 2006

Authors and Affiliations

  • Hans Axelsson
    • 1
  • Christina Lönnroth
    • 1
  • Wenhua Wang
    • 1
  • Elisabeth Svanberg
    • 1
  • Kent Lundholm
    • 1
    • 2
    Email author
  1. 1.Department of Surgery, Surgical Metabolic Research Laboratory at Lundberg Laboratory for Cancer ResearchSahlgrenska University HospitalGöteborgSweden
  2. 2.Department of Surgery, Surgical Metabolic Research Laboratory, Lundberg Laboratory for Cancer ResearchSahlgrenska University HospitalGöteborgSweden

Personalised recommendations